The estimated Net Worth of Mark Ragosa is at least 582 千$ dollars as of 1 September 2024. Mr Ragosa owns over 6,305 units of Kiniksa Pharmaceuticals International Plc stock worth over 582,067$ and over the last 4 years he sold KNSA stock worth over 0$.
Sign up
Mr A KNSA stock SEC Form 4 insiders trading
Mr has made over 15 trades of the Kiniksa Pharmaceuticals International Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 6,305 units of KNSA stock worth 153,464$ on 1 September 2024.
The largest trade he's ever made was exercising 24,248 units of Kiniksa Pharmaceuticals International Plc stock on 23 July 2024 worth over 269,153$. On average, Mr trades about 3,353 units every 64 days since 2020. As of 1 September 2024 he still owns at least 23,914 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of Mr Ragosa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Mark Ragosa C.F.A. biography
Mark Ragosa C.F.A. is the Sr. VP & CFO at Kiniksa Pharmaceuticals International Plc.
How old is Mr A?
Mr A is 46, he's been the Sr. VP & CFO of Kiniksa Pharmaceuticals International Plc since . There are 16 older and no younger executives at Kiniksa Pharmaceuticals International Plc. The oldest executive at Kiniksa Pharmaceuticals International Plc. is Barry Quart, 63, who is the Independent Director.
What's Mr A's mailing address?
Mark's mailing address filed with the SEC is , 23 OLD BOND STREET, THIRD FLOOR, LONDON, X0, W1S 4PZ.
Insiders trading at Kiniksa Pharmaceuticals International Plc
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over 11,259,873$ worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth 71,248,379$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、James E Deerfield Mgmt L.P....、Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of 1,208,067$. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth 157,309$.
What does Kiniksa Pharmaceuticals International Plc's logo look like?
Complete history of Mr Ragosa stock trades at Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals International Plc executives and stock owners
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include:
-
Sanjiv Patel,
Chairman of the Board, Chief Executive Officer -
John Paolini,
Senior Vice President and Chief Medical Officer -
Qasim Rizvi,
Senior Vice President - Operations, Chief Commercial Officer -
Sanj K. Patel,
CEO & Chairman -
Richard Levy,
Independent Director -
Felix Baker,
Lead Independent Director -
Thomas Malley,
Independent Director -
Barry Quart,
Independent Director -
Stephen Biggar,
Independent Director -
Tracey McCain,
Independent Director -
Kimberly Popovits,
Independent Director -
G. Bradley Cole,
Director -
Thomas Beetham,
Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary -
Michael Megna,
Principal Financial Officer, Chief Accounting Officer -
Dr. John F. Paolini,
Sr. VP & Chief Medical Officer -
Mei Jang,
VP of Technical Operations -
Michael R. Megna,
Chief Accounting Officer & VP of Fin. -
Christine Maurer,
Sr. VP of Program Management -
Carsten Boess,
Exec. VP of Corp. Affairs -
Rasmus Holm-Jorgensen,
Sr. VP, Chief Strategy & Portfolio Officer -
Melissa Manno,
Chief HR Officer -
Madelyn Zeylikman,
Gen. Counsel -
Chad Morin,
VP & Chief Compliance Officer -
Mark Ragosa C.F.A.,
Sr. VP & CFO -
Bros. Advisors Lp667, L.P.B...,
-
Asset Management, Lp Chen B...,
-
Stephen F. Mahoney,
President & COO -
James E Deerfield Mgmt L.P....,
-
Carsten Boess,
10% owner -
Chris Heberlig,
EVP & CFO -
Sanj K Patel,
CHAIRMAN & CEO -
Ross Moat,
CHIEF COMMERCIAL OFFICER -
Mark Ragosa,
CHIEF FINANCIAL OFFICER -
Eben Tessari,
CHIEF OPERATING OFFICER -
Arian Pano,
Chief Clinical Dev. Officer